Indigenous HPV Test Receives International Validation
India Validates Indigenous HPV Test for Affordable Cervical Cancer Screening: Researchers from AIIMS New Delhi, Indian Council of Medical Research (ICMR), and the International Agency for Research on Cancer (IARC), France have successfully validated an indigenous Human Papillomavirus (HPV) test for cervical cancer screening.
The validated test, Truenat HR-HPV-Plus, meets international performance standards and is expected to provide an affordable and accessible screening solution for women across India, especially those above 30 years of age.
Static GK fact: AIIMS New Delhi was established in 1956 under the All India Institute of Medical Sciences Act, 1956, and functions under the Ministry of Health and Family Welfare.
Why HPV Screening Remains Essential
HPV infection is the leading cause of cervical cancer, one of the most common cancers affecting women worldwide. Although HPV vaccination helps prevent future infections, regular screening remains essential for early detection of precancerous changes.
Experts recommend HPV screening for women aged 30 years and above, as early diagnosis significantly improves treatment outcomes and reduces mortality.
Static GK Tip: Cervical cancer develops in the cervix and is primarily caused by persistent infection with high-risk HPV types.
Features of Truenat HR-HPV-Plus
Among four indigenous HPV DNA tests evaluated, Truenat HR-HPV-Plus, developed by Molbio Diagnostics, was the only test to satisfy all international validation criteria established by WHO and IARC.
The test detects eight high-risk HPV types responsible for nearly 95% of cervical cancer cases. It also demonstrated high accuracy, reliable reproducibility across laboratories, and suitability for use in district and sub-district healthcare facilities.
Static GK fact: Molbio Diagnostics is an Indian biotechnology company known for developing the Truenat molecular diagnostic platform.
Validation Study and Public Health Significance
The validation study was supported by the Department of Biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC) under the Grand Challenges India initiative.
Researchers evaluated four Indian-developed HPV tests using 1,159 cervical samples, including confirmed precancerous lesions and cervical cancer cases. The study followed internationally accepted WHO and IARC validation benchmarks.
Static GK Tip: BIRAC is a not-for-profit public sector enterprise under the Department of Biotechnology, promoting innovation in biotechnology and healthcare.
Impact on India’s Healthcare System
The validated indigenous test is expected to reduce India’s dependence on imported HPV screening technologies and lower the cost of large-scale cervical cancer screening.
Its compatibility with the existing Truenat diagnostic infrastructure will enable rapid deployment in rural and semi-urban healthcare centres, improving access to early detection and supporting India’s efforts to reduce cervical cancer burden.
Static GK fact: ICMR, established in 1911 and headquartered in New Delhi, is India’s apex body for biomedical research under the Ministry of Health and Family Welfare.
Static Usthadian Current Affairs Table
India Validates Indigenous HPV Test for Affordable Cervical Cancer Screening:
| Fact | Detail |
| Validated Test | Truenat HR-HPV-Plus |
| Developed By | Molbio Diagnostics |
| Validation Agencies | AIIMS New Delhi, ICMR and IARC |
| Disease Targeted | Cervical Cancer |
| Primary Cause | Human Papillomavirus (HPV) infection |
| High-Risk HPV Types Detected | Eight |
| Cervical Samples Evaluated | 1,159 |
| Supporting Initiative | DBT-BIRAC Grand Challenges India |
| International Standards | WHO and IARC validation criteria |
| Major Benefit | Affordable and accessible cervical cancer screening |
